ClinicalTrials.gg
CompletedNCT01917656LIRA-Ramadan™Updated Aug 24, 2017Results posted

Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes

A Phase 4 interventional study of liraglutide and metformin in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 41 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-24.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
343
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.

Enrollment
33rd of 151
343 · median 62
Started
2014
with 12 others
Phase 4
48 of 151
1 open now
Registered
80th of 151
by date
Lead sponsor
63 of 151
Novo Nordisk A/S

Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 33rd largest by enrollment, is one of 13 that started in 2014, is one of 48 in phase 4, and was the 80th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies testing liraglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Africa and Asia. The aim of the trial is to investigate the efficacy and safety of liraglutide versus sulphonylurea (SU) both in combination with metformin during Ramadan in subjects with type 2 diabetes (T2DM).

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 343 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Subjects diagnosed with T2DM and treated with metformin equal to or above 1000 mg/day and SU (gliclazide, glipizide or glyburide/glibenclamide at maximum tolerated dose (at least half maximum approved dose) or glimepiride at maximum tolerated dose (at least 2 mg/day)), both at a stable dose for at least 90 days prior to screening. Stable is defined as unchanged medication and dose
    • 7.0-10.0% (53- 86 mmol/mol) (both inclusive)
    • (BMI) equal to or above 20 kg/m\^2
    • Subjects who have expressed their intention to fast (daytime, i.e. between sunrise and sunset) during Ramadan after receiving medical counselling regarding the risk of fasting

Exclusion criteria

Exclusion Criteria:

    • Any for successful and sustained fasting from a medical perspective at the discretion of the investigator (such as acute illness, severe hypoglycaemia within 90 days prior to screening, a history of recurrent hypoglycaemia, hypoglycaemia unawareness, ketoacidosis within 90 days prior to screening, hyperosmolar hyperglycaemic coma within 90 days prior to screening, subjects performing intense physical labour)
    • Any chronic disorder or severe disease which, in the opinion of the investigator might jeopardise subject's safety or compliance with the protocol
    • History of chronic pancreatitis or idiopathic acute pancreatitis
    • Screening calcitonin value equal to or above 50 ng/L
    • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2)
    • Impaired liver function, defined as (ALAT) equal to or above 2.5 times upper normal limit (UNL)
    • Impaired renal function defined as estimated (eGFR) below 60 mL/min/1.73 m\^2 per Modification of Diet in Renal Disease (MDRD) formula)
    • Any episode of unstable angina, acute coronary event, cerebral stroke/ (TIA) or other significant cardiovascular event as judged by the investigator within 90 days prior to screening
    • Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin cancer or squamous cell skin cancer)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
343 participants (actual)

Study arms

  • Experimental
    Liraglutide+Metformin

    Liraglutide 1.8 mg administered once daily subcutaneously, in combination with pre-trial tablet metformin of unchanged dose.

    Drug: liraglutide · Drug: metformin

  • Active comparator
    Sulphonylurea and Metformin

    Subjects continued on pre-trial sulphonylurea tablet treatment, in combination with pre-trial tablet metformin of unchanged dose.

    Drug: metformin · Drug: sulphonylurea

Interventions

  • 1.8 mg administered subcutaneously (s.c., under the skin) once daily

  • Subjects will continue on their pre-trial metformin tablet treatment, dose unchanged

  • Drugsulphonylurea

    Subjects will continue on their pre-trial SU tablet treatment, doses unchanged

07

What researchers measure

Primary outcomes

  1. Change in Fructosamine From Start of Ramadan to End of Ramadan

    The level of fructosamine in the blood was used to assess the glycaemic control in the patients during the time period described- from start of Ramadan (day -1, visit 8) to end of Ramadan (day 29, visit 12).

    Time frame: Day -1, day 29

Secondary outcomes

  1. Fructosamine at End of Ramadan

    The fructosamine values at the end of Ramadan (visit 12) were presented

    Time frame: Day 29

  2. Change From Start of Ramadan to End of Ramadan in Fasting Plasma Glucose (FPG)

    The level of FPG in the blood of fasting patients was addressed to monitor glycaemic control during the period described.

    Time frame: Day -1, day 29

  3. Change From Baseline to End of Ramadan in Fasting Plasma Glucose

    The changes from baseline measured postbaseline (i.e., the changes measured on visit 8 and 12) entered as the dependent variables, and visit, treatment, country, and the stratification variables were included as fixed factors and the corresponding values for the specific endpoint measured at randomisation as covariate.

    Time frame: Baseline, day 29

  4. Change From Baseline to End of Ramadan in Glycosylated Haemoglobin (HbA1c)

    The level of glycosylated haemoglobin in blood was used to assess the glycaemic control of the patients during the time period described.

    Time frame: Baseline, day 29

  5. Change From Baseline to End of Ramadan in Body Weight

    Time frame: Baseline, day 29

  6. Subjects Who at End of Treatment (4 Weeks Post Ramadan) Achieve (y/n): HbA1c Below 7.0% (53 mmol/Mol) (ADA Target)

    Subjects who at end of treatment (Visit 14, 4 weeks post Ramadan) achieve (y/n): HbA1c below 7.0% (53 mmol/mol) (ADA target)

    Time frame: Visit 14 (4 weeks post Ramadan)

  7. Subjects Who at End of Treatment (4 Weeks Post Ramadan) Achieve (y/n): HbA1c Below 7.0% (53 mmol/Mol), and no Confirmed Hypoglycaemic Episodes

    Subjects who at end of treatment (Visit 14, 4 weeks post Ramadan) achieve (y/n): HbA1c below 7.0% (53 mmol/mol) (ADA target)

    Time frame: Visit 14 (4 weeks post Ramadan)

  8. Number of Confirmed Hypoglycaemic Episodes During Ramadan (Fasting), Based on Each Subject's Individual Fasting Period.

    Time frame: Day -1 to day 29

  9. Number of Treatment Emergent Adverse Events (TEAEs) During Ramadan (Fasting), Based on Each Subject's Individual Fasting Period.

    A serious AE was an experience that at any dose resulted in any of the following: Death, a life-threatening experience, in-patient hospitalisation or prolongation of existing hospitalisation, a persistent or significant disability or incapacity, congenital anomaly or birth defect, important medical events. Mild - no or transient symptoms, no interference with the subject's daily activities Moderate - marked symptoms, moderate interference with the subject's daily activities Severe - considerable interference with the subject's daily activities, unacceptable

    Time frame: Day -1 to day 29

08

Results

Posted Oct 7, 2015

Participant flow

The trial was conducted at 39 sites in 7 countries as follows: Algeria: 7 sites; Israel: 4 sites; India: 5 sites; Lebanon: 2 sites; Malaysia: 7 sites; South Africa: 8 sites; United Arab Emirates: 6 sites

Participant flow — Overall Study
MilestoneLiraglutide and MetforminSulfonylurea and Metformin
Started172171
Exposed171170
Exposed during ramadan (fasting)152163
Completed146147
Not completed2624
Withdrew: Adverse event110
Withdrew: Withdrawal criteria814
Withdrew: Unclassified03
Withdrew: Withdrawal by subject43
Withdrew: Lost to follow-up34

Outcome measures

PrimaryChange in Fructosamine From Start of Ramadan to End of Ramadan

The level of fructosamine in the blood was used to assess the glycaemic control in the patients during the time period described- from start of Ramadan (day -1, visit 8) to end of Ramadan (day 29, visit 12).

Time frame:
Day -1, day 29
Reported as:
Mean · umol/L
Change in Fructosamine From Start of Ramadan to End of Ramadan
umol/LLiraglutide and MetforminSulfonylurea and Metformin
Change in Fructosamine From Start of Ramadan to End of Ramadan-13.2 ± 36.0-14.9 ± 43.0
SecondaryFructosamine at End of Ramadan

The fructosamine values at the end of Ramadan (visit 12) were presented

Time frame:
Day 29
Reported as:
Mean · umol/L
Fructosamine at End of Ramadan
umol/LLiraglutide and MetforminSulfonylurea and Metformin
Fructosamine at End of Ramadan276.8 ± 44.1284.9 ± 46.6
SecondaryChange From Start of Ramadan to End of Ramadan in Fasting Plasma Glucose (FPG)

The level of FPG in the blood of fasting patients was addressed to monitor glycaemic control during the period described.

Time frame:
Day -1, day 29
Reported as:
Mean · mmol/L
Change From Start of Ramadan to End of Ramadan in Fasting Plasma Glucose (FPG)
mmol/LLiraglutide and MetforminSulfonylurea and Metformin
Change From Start of Ramadan to End of Ramadan in Fasting Plasma Glucose (FPG)-0.1 ± 2.00.1 ± 3.8
SecondaryChange From Baseline to End of Ramadan in Fasting Plasma Glucose

The changes from baseline measured postbaseline (i.e., the changes measured on visit 8 and 12) entered as the dependent variables, and visit, treatment, country, and the stratification variables were included as fixed factors and the corresponding values for the specific endpoint measured at randomisation as covariate.

Time frame:
Baseline, day 29
Reported as:
Mean · mmol/L
Change From Baseline to End of Ramadan in Fasting Plasma Glucose
mmol/LLiraglutide and MetforminSulfonylurea and Metformin
Change From Baseline to End of Ramadan in Fasting Plasma Glucose-1.8 ± 3.1-0.6 ± 3.6
SecondaryChange From Baseline to End of Ramadan in Glycosylated Haemoglobin (HbA1c)

The level of glycosylated haemoglobin in blood was used to assess the glycaemic control of the patients during the time period described.

Time frame:
Baseline, day 29
Reported as:
Mean · Percent (%) glycosylated haemoglobin
Change From Baseline to End of Ramadan in Glycosylated Haemoglobin (HbA1c)
Percent (%) glycosylated haemoglobinLiraglutide and MetforminSulfonylurea and Metformin
Change From Baseline to End of Ramadan in Glycosylated Haemoglobin (HbA1c)-1.3 ± 1.1-0.7 ± 0.9
SecondaryChange From Baseline to End of Ramadan in Body Weight
Time frame:
Baseline, day 29
Reported as:
Least squares mean · kg
Change From Baseline to End of Ramadan in Body Weight
kgLiraglutide and MetforminSulfonylurea and Metformin
Change From Baseline to End of Ramadan in Body Weight-5.40 ± 0.2205-1.46 ± 0.2139
SecondarySubjects Who at End of Treatment (4 Weeks Post Ramadan) Achieve (y/n): HbA1c Below 7.0% (53 mmol/Mol) (ADA Target)

Subjects who at end of treatment (Visit 14, 4 weeks post Ramadan) achieve (y/n): HbA1c below 7.0% (53 mmol/mol) (ADA target)

Time frame:
Visit 14 (4 weeks post Ramadan)
Reported as:
Number · percentage (%) of subjects
Subjects Who at End of Treatment (4 Weeks Post Ramadan) Achieve (y/n): HbA1c Below 7.0% (53 mmol/Mol) (ADA Target)
percentage (%) of subjectsLiraglutide and MetforminSulfonylurea and Metformin
Subjects Who at End of Treatment (4 Weeks Post Ramadan) Achieve (y/n): HbA1c Below 7.0% (53 mmol/Mol) (ADA Target)51.029.9
SecondarySubjects Who at End of Treatment (4 Weeks Post Ramadan) Achieve (y/n): HbA1c Below 7.0% (53 mmol/Mol), and no Confirmed Hypoglycaemic Episodes

Subjects who at end of treatment (Visit 14, 4 weeks post Ramadan) achieve (y/n): HbA1c below 7.0% (53 mmol/mol) (ADA target)

Time frame:
Visit 14 (4 weeks post Ramadan)
Reported as:
Number · percentage (%) of subjects
Subjects Who at End of Treatment (4 Weeks Post Ramadan) Achieve (y/n): HbA1c Below 7.0% (53 mmol/Mol), and no Confirmed Hypoglycaemic Episodes
percentage (%) of subjectsLiraglutide and MetforminSulfonylurea and Metformin
Subjects Who at End of Treatment (4 Weeks Post Ramadan) Achieve (y/n): HbA1c Below 7.0% (53 mmol/Mol), and no Confirmed Hypoglycaemic Episodes47.625.2
SecondaryNumber of Confirmed Hypoglycaemic Episodes During Ramadan (Fasting), Based on Each Subject's Individual Fasting Period.
Time frame:
Day -1 to day 29
Reported as:
Number · Events/1000 years of patient exposure
Number of Confirmed Hypoglycaemic Episodes During Ramadan (Fasting), Based on Each Subject's Individual Fasting Period.
Events/1000 years of patient exposureLiraglutide and MetforminSulfonylurea and Metformin
Number of Confirmed Hypoglycaemic Episodes During Ramadan (Fasting), Based on Each Subject's Individual Fasting Period.246623
SecondaryNumber of Treatment Emergent Adverse Events (TEAEs) During Ramadan (Fasting), Based on Each Subject's Individual Fasting Period.

A serious AE was an experience that at any dose resulted in any of the following: Death, a life-threatening experience, in-patient hospitalisation or prolongation of existing hospitalisation, a persistent or significant disability or incapacity, congenital anomaly or birth defect, important medical events. Mild - no or transient symptoms, no interference with the subject's daily activities Moderate - marked symptoms, moderate interference with the subject's daily activities Severe - considerable interference with the subject's daily activities, unacceptable

Time frame:
Day -1 to day 29
Reported as:
Number · Events/1000 years of patient exposure
Number of Treatment Emergent Adverse Events (TEAEs) During Ramadan (Fasting), Based on Each Subject's Individual Fasting Period.
Events/1000 years of patient exposureLiraglutide and MetforminSulfonylurea and Metformin
Adverse events52583349
Serious adverse events1640
Severe adverse events41178
Moderate adverse event986779
Mild adverse event38612492

Adverse events

Collected over A treatment emergent AE during Ramadan (fasting) had onset on or after the individual subject's first day of Ramadan fasting, and no later than the individual subject's last day of Ramadan fasting.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Liraglutide and Metformin—2/152 (1.3%)8/152 (5.3%)
Sulfonylurea and Metformin—0/163 (0%)1/163 (0.6%)
Most frequent serious events
Most frequent serious events
EventLiraglutide and MetforminSulfonylurea and Metformin
Abscess limbInfections and infestations1/1520/163
GastroenteritisInfections and infestations1/1520/163
Most frequent other events
Most frequent other events
EventLiraglutide and MetforminSulfonylurea and Metformin
VomitingGastrointestinal disorders8/1521/163

Baseline characteristics

Safety analysis set

Age, Continuous
Age, Continuous(years)Liraglutide and MetforminSulfonylurea and MetforminTotal
Mean54.9 ± 9.2754.0 ± 9.3354.5 ± 9.30
Sex: Female, Male
Sex: Female, Male(Participants)Liraglutide and MetforminSulfonylurea and MetforminTotal
Female8687173
Male8583168
09

Study locations

41 sites
  • Novo Nordisk Investigational Site
    Algiers, 16000, Algeria
  • Novo Nordisk Investigational Site
    Constantine, 25000, Algeria
  • Novo Nordisk Investigational Site
    Oran, 31000, Algeria
  • Novo Nordisk Investigational Site
    Setif, 19000, Algeria
  • Novo Nordisk Investigational Site
    Sidi Bel Abbes, 22000, Algeria
  • Novo Nordisk Investigational Site
    Hyderabad, Andhra Pradesh 500034, India
  • Novo Nordisk Investigational Site
    Ahmedabad, Gujarat 380007, India
  • Novo Nordisk Investigational Site
    Bangalore, Karnataka 560002, India
  • Novo Nordisk Investigational Site
    Mysore, Karnataka 570001, India
  • Novo Nordisk Investigational Site
    Mysore, Karnataka 570004, India
  • Novo Nordisk Investigational Site
    Mumbai, Maharashtra 400008, India
  • Novo Nordisk Investigational Site
    Mumbai, Maharashtra 400010, India
  • Novo Nordisk Investigational Site
    Mumbai, Maharashtra 400058, India
  • Novo Nordisk Investigational Site
    Pune, Maharashtra 411001, India
  • Novo Nordisk Investigational Site
    Beer Sheva, 84101, Israel
  • Novo Nordisk Investigational Site
    Haifa, 31096, Israel
  • Novo Nordisk Investigational Site
    Haifa, 35152, Israel
  • Novo Nordisk Investigational Site
    Jerusalem, 93106, Israel
  • Novo Nordisk Investigational Site
    Beirut, Lebanon
  • Novo Nordisk Investigational Site
    Lebanon - Beirut, 9611, Lebanon
  • Novo Nordisk Investigational Site
    Cheras, 56000, Malaysia
  • Novo Nordisk Investigational Site
    Ipoh, Perak, 30990, Malaysia
  • Novo Nordisk Investigational Site
    Klang, Selangor, 41200, Malaysia
  • Novo Nordisk Investigational Site
    Kota Bharu, Kelantan, 16150, Malaysia
  • Novo Nordisk Investigational Site
    Putrajaya, 62250, Malaysia
  • Novo Nordisk Investigational Site
    Selangor Darul Ehsan, 68000, Malaysia
  • Novo Nordisk Investigational Site
    Seremban, Negeri Sembilan, 70400, Malaysia
  • Novo Nordisk Investigational Site
    Benoni, Gauteng 1501, South Africa
  • Novo Nordisk Investigational Site
    Johannesburg, Gauteng 1812, South Africa
  • Novo Nordisk Investigational Site
    Johannesburg, Gauteng 1827, South Africa
  • Novo Nordisk Investigational Site
    Lenasia, Gauteng 1827, South Africa
  • Novo Nordisk Investigational Site
    Pretoria, Gauteng 0181, South Africa
  • Novo Nordisk Investigational Site
    Durban, KwaZulu-Natal 4091, South Africa
  • Novo Nordisk Investigational Site
    Durban, KwaZulu-Natal 4092, South Africa
  • Novo Nordisk Investigational Site
    Durban, KwaZulu-Natal 4450, South Africa
  • Novo Nordisk Investigational Site
    Ajman, 21499, United Arab Emirates
  • Novo Nordisk Investigational Site
    Dubai, 4545, United Arab Emirates
  • Novo Nordisk Investigational Site
    Dubai, 9115, United Arab Emirates
  • Novo Nordisk Investigational Site
    Ras Al Khaimah, 4727, United Arab Emirates
  • Novo Nordisk Investigational Site
    Sharjah, 3500, United Arab Emirates
  • Novo Nordisk Investigational Site
    Umm Al Quwain, 24, United Arab Emirates
10

References and documents

Publications

  • Azar ST, Echtay A, Wan Bebakar WM, Al Araj S, Berrah A, Omar M, Mutha A, Tornoe K, Kaltoft MS, Shehadeh N. Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial. Diabetes Obes Metab. 2016 Oct;18(10):1025-33. doi: 10.1111/dom.12733. Epub 2016 Aug 18. PubMed 27376711 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in Sep 2014, 7 months.

Results were first posted in Oct 2015, 1 year 1 month after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 7 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2013
First posted
Aug 7, 2013
StartActual
Jan 9, 2014
Primary completionActual
Sep 1, 2014
CompletionActual
Sep 4, 2014
Results first posted
Oct 7, 2015
Last update
Aug 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01917656
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 7, 2013
Start date
Jan 9, 2014
Primary completion
Sep 1, 2014
Completion
Sep 4, 2014
Results posted
Oct 7, 2015
Last update
Aug 24, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion